蛋白质精氨酸甲基转移酶5
甲基转移酶
药理学
体内
IC50型
精氨酸
化学
表观遗传疗法
癌症研究
细胞毒性
医学
甲基化
体外
生物化学
生物
氨基酸
DNA甲基化
生物技术
基因表达
基因
作者
Yixuan Tang,Shihui Huang,Xingxing Chen,Junzhang Huang,Qianwen Lin,Lei Huang,Shuping Wang,Qihua Zhu,Yungen Xu,Yi Zou
出处
期刊:Molecules
[Multidisciplinary Digital Publishing Institute]
日期:2022-10-06
卷期号:27 (19): 6637-6637
标识
DOI:10.3390/molecules27196637
摘要
Protein arginine methyltransferases 5 (PRMT5) is a clinically promising epigenetic target that is upregulated in a variety of tumors. Currently, there are several PRMT5 inhibitors under preclinical or clinical development, however the established clinical inhibitors show favorable toxicity. Thus, it remains an unmet need to discover novel and structurally diverse PRMT5 inhibitors with characterized therapeutic utility. Herein, a series of tetrahydroisoquinoline (THIQ) derivatives were designed and synthesized as PRMT5 inhibitors using GSK-3326595 as the lead compound. Among them, compound 20 (IC50: 4.2 nM) exhibits more potent PRMT5 inhibitory activity than GSK-3326595 (IC50: 9.2 nM). In addition, compound 20 shows high anti-proliferative effects on MV-4-11 and MDA-MB-468 tumor cells and low cytotoxicity on AML-12 hepatocytes. Furthermore, compound 20 possesses acceptable pharmacokinetic profiles and displays considerable in vivo antitumor efficacy in a MV-4-11 xenograft model. Taken together, compound 20 is an antitumor compound worthy of further study.
科研通智能强力驱动
Strongly Powered by AbleSci AI